Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential vs Bismuth Quadruple Therapy for Second-Line H. Pylori Eradication
NCT03208426Phase 4Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Oct 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of esomeprazole, amoxicillin, clarithromycin and metronidazole in Helicobacter pylori infection (2 arms), sponsored by National Taiwan University Hospital. Primary endpoint: Eradication rate in the second line treatment according to intention to treat (ITT) analysis at 6 weeks. Status: unknown.
02
Drugs
esomeprazoleamoxicillinclarithromycinmetronidazole
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT03208426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03208426.